In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Atossa Genetics (ATOS), with a price target of $5. The company’s shares closed yesterday at $1.29, close to its 52-week low of $1.15.
McCarthy wrote:
“Atossa reported 3Q18 with a net loss of ($3.3M) and ended the period with $13M in cash on the balance sheet. We estimate Atossa has sufficient runway into 2H19.”
According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -1.5% and a 30.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Atossa Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
Based on Atossa Genetics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $4.14 million. In comparison, last year the company had a GAAP net loss of $2.18 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests.
